Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paulinder Rai

Physical Medicine & Rehabilitation Brightwaters, NY Doctor of Osteopathy

NPI 1568604478 CMS profile 207217

234 Orinoco Dr, Brightwaters, NY 11718

Open in the dashboard

General payments

$8,798

222 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paulinder Rai of Brightwaters, NY is reported in the CMS Open Payments database as having received $8,798 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $764 28
2024 General $992 31
2023 General $676 24
2022 General $803 29
2021 General $1,343 41
2020 General $536 23
2019 General $3,685 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paulinder Rai
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Paulinder Rai were reported at $764. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Paulinder Rai Physical Medicine & Rehabilitation median Middle half National median
2019 $3,685 $133 $45–$390 $163
2020 $536 $88 $29–$272 $114
2021 $1,343 $116 $33–$360 $132
2022 $803 $123 $40–$378 $149
2023 $676 $131 $43–$396 $160
2024 $992 $141 $45–$409 $164
2025 $764 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,228 18 payments
  2. Smith+Nephew, Inc. $1,331 56 payments
  3. Organogenesis Inc. $1,147 47 payments
  4. AbbVie, Inc. $591 16 payments
  5. Tactile Systems Technology Inc $466 17 payments
  6. Misonix Inc $434 22 payments
  7. Ipsen Biopharmaceuticals, Inc $340 6 payments
  8. Medtronic, Inc. $339 4 payments
  9. KCI USA, Inc $261 3 payments
  10. Urovant Sciences Inc $249 2 payments
  11. Other $1,411 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,225 219 payments
  2. Travel and Lodging $1,447 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $126 1 payment
Products named General payments · program years 2019–2025
  1. SYNCHROMED $1,440 10 payments
  2. DALVANCE $591 16 payments
  3. COLLAGENASE SANTYL $546 29 payments
  4. Puraply $516 23 payments
  5. LIORESAL $459 1 payment
  6. Flexitouch Plus $452 16 payments
  7. DYSPORT $340 6 payments
  8. MYSTIM $316 6 payments
  9. entre $275 9 payments
  10. Santyl $262 7 payments
  11. Other $4,641 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

323

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$4,062

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

12.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Baclofen Generic 85 $1,314
Gabapentin Generic 43 $855
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 20 $484
Duloxetine Hcl Generic 27 $373
Silver Sulfadiazine Generic 14 $361
Mupirocin Generic 41 $281
Tizanidine Hcl Generic 12 $121
Doxycycline Hyclate Generic 30 $98
Tramadol Hcl Generic 18 $77
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $71

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$726,200

Of which drugs: $68,256

Medicare patients

2,852

Average age 77

Services billed

24,838

1,460 women, 1,392 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Ischemic heart disease 62%
Diabetes 56%
Depression 50%
Chronic kidney disease 46%
Heart failure 45%
Atrial fibrillation 40%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abobotulinumtoxina, 5 units J0586 Office 21 9,240 $63,335

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $213
$213 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $24
$24 — 9,240
TEFLARO
  • AbbVie, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record